Evidence map›Paper›PMID 29170501›Full record

ReviewNature reviews. Neurology2018

Idiopathic REM sleep behaviour disorder and neurodegeneration - an update.

Birgit Högl, Ambra Stefani, Aleksandar Videnovic

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 6 pooled it
26.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

227 citing papers in PubMed, 6 syntheses or guidelines pooled it, 522 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Baseline characteristics of the North American prodromal Synucleinopathy cohort.Annals of clinical and translational neurology · 2023
    Trial
  9. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial.Movement disorders : official journal of the Movement Disorder Society · 2020
    Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. A gradual and sustainable approach to diagnosing sleep and circadian disturbances in dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  20. Observational

167 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Birgit HöglDepartment of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Ambra StefaniDepartment of Neurology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.
Aleksandar VidenovicDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, Suite 600, Boston, Massachusetts 02114, USA.
Innsbruck Medical University · ATMassachusetts General Hospital · US

Funding

Bright light modulation of non-motor symptoms in Parkinson's diseaseR01NS099055 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI VIDENOVIC, ALEKSANDAR · 2017 to 2021
$3.0M
Circadian Rhythms and Sleep-Wake Cycles in Parkinson's DiseaseK23NS072283 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI VIDENOVIC, ALEKSANDAR · 2012 to 2017
$935k
Austrian Science Fund FWF I 2120NINDS NIH HHS K23 NS072283NINDS NIH HHS R01 NS099055
6 · The paper itself

Abstract

So-called idiopathic rapid eye movement (REM) sleep behaviour disorder (RBD), formerly seen as a rare parasomnia, is now recognized as the prodromal stage of an α-synucleinopathy. Given the very high risk that patients with idiopathic RBD have of developing α-synucleinopathies, such as Parkinson disease (PD), PD dementia, dementia with Lewy bodies or multiple system atrophy, and the outstandingly high specificity and very long interval between the onset of idiopathic RBD and the clinical manifestations of α-synucleinopathies, the prodromal phase of this disorder represents a unique opportunity for potentially disease-modifying intervention. This Review provides an update on classic and novel biomarkers of α-synuclein-related neurodegeneration in patients with idiopathic RBD, focusing on advances in imaging and neurophysiological, cognitive, autonomic, tissue-specific and other biomarkers. We discuss the strengths, potential weaknesses and suitability of these biomarkers for identifying RBD and neurodegeneration, with an emphasis on predicting progression to overt α-synucleinopathy. The role of video polysomnography in providing quantifiable and potentially treatment-responsive biomarkers of neurodegeneration is highlighted. In light of all these advances, and the now understood role of idiopathic RBD as an early manifestation of α-synuclein disease, we call for idiopathic RBD to be reconceptualized as isolated RBD.

Indexed as

alpha-SynucleinBiomarkersHumansNeurodegenerative DiseasesREM Sleep Behavior Disorderalpha-SynucleinBiomarkers

Identifiers

PMID29170501
OpenAlexW2768364432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.